Virtu Financial LLC Makes New $100,000 Investment in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Virtu Financial LLC bought a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 17,692 shares of the company’s stock, valued at approximately $100,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Intech Investment Management LLC bought a new position in Voyager Therapeutics during the 3rd quarter worth $74,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Voyager Therapeutics by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock worth $804,000 after purchasing an additional 3,473 shares in the last quarter. FMR LLC increased its position in shares of Voyager Therapeutics by 26.9% in the third quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after purchasing an additional 19,622 shares during the period. BNP Paribas Financial Markets raised its stake in Voyager Therapeutics by 30.5% in the third quarter. BNP Paribas Financial Markets now owns 49,235 shares of the company’s stock valued at $288,000 after purchasing an additional 11,516 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in Voyager Therapeutics during the third quarter worth about $216,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Stock Down 2.4 %

Shares of VYGR opened at $3.65 on Monday. The stock has a market cap of $201.51 million, a PE ratio of 5.14 and a beta of 0.99. Voyager Therapeutics, Inc. has a 12-month low of $3.56 and a 12-month high of $10.66. The business has a 50-day simple moving average of $4.51 and a two-hundred day simple moving average of $5.64.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The business had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter last year, the company posted $1.25 earnings per share. On average, equities research analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on VYGR shares. Canaccord Genuity Group decreased their target price on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, March 13th. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Citigroup initiated coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday, March 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $13.97.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.